Enbrel All Financial Data in US $ (mln)
Worldwide
 
Overview
 

Word Search (Top 10 - by date)

PFIZER REPORTS THIRD-QUARTER 2014 RESULTS
Pfizer (October 28, 2014)
Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans
Amgen (October 28, 2014)
Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30
Amgen (October 27, 2014)
Novartis Data at EADV Show Consistent Efficacy of AIN457 (secukinumab) in Clearing Skin of Psoriasis Patients
Novartis (October 10, 2014)
Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology
Amgen (October 01, 2014)
Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel
XenoPort (September 02, 2014)
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease
Pfizer (August 28, 2014)
Initiation of Phase 3 Trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody)
Daiichi Sankyo (August 18, 2014)
CDRD Ventures Inc. Boosts Commercialization Power with New Additions to Senior Management Team
The Centre for Drug Research and Development (August 01, 2014)
Summary of Financial Statements for the Three Month Period Ended June 30, 2014 (IFRS, Consolidated)
Takeda (August 01, 2014)

Displaying 10 out of a possible 621 unique stories.
Results Sorted By date
Display All Stories


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Enbrel
Generic Name:   etanercept
Therapeutic Subcategory:     Other anti-rheumatics
Therapeutic Subcategory:     Anti-virals

Product Sales Summary 2010/11

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2010 2011 2011
Enbrel2 7,257 7,892 +9%
Note: Shaded Cells3

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Enbrel4 396

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product: Enbrel

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now